Macrogenics: Margetuximab for HER2 Gastric Cancer - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn if the study drugs are safe for patients, if they can reduce or slow the growth of your cancer, and what effects, good or bad, these drugs may have on your body.
Who Can Participate in the Study?
- Have unresectable HER2 positive gastric cancer
What is Involved?
If you choose to join this study, you will:
- Receive both margetuximab and pembrolizumab given once every 3 weeks
-- Both pembrolizumab and margetuximab will be given by injection into your vein in the clinic at Duke